Evidence map›Paper›PMID 33340419›Full record

ArticleBiopharmaceutics & drug disposition2021

Physiologically based pharmacokinetic model of renally cleared antibacterial drugs in Chinese renal impairment patients.

Cheng Cui, Xiaobei Li, Hao Liang, Zhe Hou, Siqi Tu, Zhongqi Dong, Xueting Yao, Miao Zhang, Xuan Zhang, Haiyan Li and 2 more

Open access · hybridAbstract read
In one paragraph

Article in Biopharmaceutics & drug disposition, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.5field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. A physiologically based pharmacokinetic model of cefepime to predict its pharmacokinetics in healthy, pediatric and disease populations.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2023
    Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Cheng CuiDrug Clinical Trial Center, Peking University Third Hospital, Beijing, People's Republic of China.ORCID https://orcid.org/0000-0001-6446-0127
Xiaobei LiDrug Clinical Trial Center, Peking University Third Hospital, Beijing, People's Republic of China.
Hao LiangDrug Clinical Trial Center, Peking University Third Hospital, Beijing, People's Republic of China.
Zhe HouDrug Clinical Trial Center, Peking University Third Hospital, Beijing, People's Republic of China.
Siqi TuDrug Clinical Trial Center, Peking University Third Hospital, Beijing, People's Republic of China.
Zhongqi DongJanssen China R&D Center, Shanghai, People's Republic of China.
Xueting YaoDrug Clinical Trial Center, Peking University Third Hospital, Beijing, People's Republic of China.
Miao ZhangDrug Clinical Trial Center, Peking University Third Hospital, Beijing, People's Republic of China.
Xuan ZhangSchool of Pharmaceutical Sciences, Peking University, Beijing, People's Republic of China.
Haiyan LiDrug Clinical Trial Center, Peking University Third Hospital, Beijing, People's Republic of China.
Xiaocong ZuoCenter of Clinical Pharmacology, Third Xiangya Hospital, Central South University, Changsha, People's Republic of China.
Dongyang LiuDrug Clinical Trial Center, Peking University Third Hospital, Beijing, People's Republic of China.ORCID https://orcid.org/0000-0002-0608-8192
Peking University · CNCentral South University · CN

Funding

Bill and Melinda Gates Foundation OPP1204780
6 · The paper itself

Abstract

To preliminarily develop physiologically based population models for Chinese renal impairment patients and to evaluate the prediction performance of new population models by renally cleared antibacterial drugs. First, demographic data and physiological parameters of Chinese renal impairment patients were collected, and then the coefficients of the relative demographic and physiological equation were recalibrated to construct the new population models. Second, drug-independent parameters of ceftazidime, cefodizime, vancomycin, and cefuroxime were collected and verified by Chinese healthy volunteers, Caucasian healthy volunteers, and Caucasian renal impairment population models built in Simcyp. Finally, the newly developed population models were applied to predict the plasma concentration of four antibacterial drugs in Chinese renal impairment patients. The new physiologically based pharmacokinetic (PBPK) population models can predict the main pharmacokinetic parameters, including area under the plasma concentration-time curve extrapolated to infinity (AUC

Indexed as

AdolescentAdultAgedAged, 80 and overAnti-Bacterial AgentsFemaleHumansKidneyMaleMetabolic Clearance RateMiddle AgedModels, BiologicalRenal InsufficiencyYoung AdultAnti-Bacterial AgentsChinese renal impairment patientsphysiologically based pharmacokinetic modelpredictive performancerenally cleared antibacterial drugs

Identifiers

PMID33340419
PMCPMC7898311
OpenAlexW3117031070

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.